<?xml version="1.0"?>
<metadata xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dc="http://purl.org/dc/elements/1.1/"><dc:title>Redox active or thiol reactive?</dc:title><dc:creator>Proj,	Matic	(Avtor)
	</dc:creator><dc:creator>Knez,	Damijan	(Avtor)
	</dc:creator><dc:creator>Sosič,	Izidor	(Avtor)
	</dc:creator><dc:creator>Gobec,	Stanislav	(Avtor)
	</dc:creator><dc:subject>redox</dc:subject><dc:subject>covalent</dc:subject><dc:subject>screening</dc:subject><dc:subject>hits</dc:subject><dc:subject>PAINS</dc:subject><dc:subject>assays</dc:subject><dc:description>Compounds that exhibit assay interference or undesirable mechanisms of bioactivity are routinely encountered in assays at various stages of drug discovery. We observed that assays for the investigation of thiol-reactive and redox-active compounds have not been collected in a comprehensive review. Here, we review these assays and subject them to experimental optimization to improve their reliability. We demonstrate the usefulness of our assay cascade by assaying a library of bioactive compounds, chemical probes, and a set of approved drugs. These high-throughput assays should complement the array of wet-lab and in silico assays during the initial stages of hit discovery campaigns to pursue only hit compounds with tractable mechanisms of action.</dc:description><dc:date>2022</dc:date><dc:date>2022-08-30 13:06:04</dc:date><dc:type>Članek v reviji</dc:type><dc:identifier>139090</dc:identifier><dc:identifier>UDK: 615.4:54</dc:identifier><dc:identifier>ISSN pri članku: 1359-6446</dc:identifier><dc:identifier>DOI: 10.1016/j.drudis.2022.03.008</dc:identifier><dc:identifier>COBISS_ID: 100881923</dc:identifier><dc:language>sl</dc:language></metadata>
